This trial will compare two different treatments for leiomyosarcoma, a type of cancer. One treatment will be the standard of care, and the other will be a new treatment that includes a drug called unesbulin. The trial will look at whether the new treatment is more effective and has fewer side effects than the standard treatment.
1 Primary · 5 Secondary · Reporting Duration: From the date of randomization up to approximately 2 years
345 Total Participants · 2 Treatment Groups
Primary Treatment: Unesbulin · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: